Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full |
| _version_ | 1797852908159500288 |
|---|---|
| author | Yanfei Liu Yuqin Song Shubo Zuo Xian Zhang Hui Liu Jingwen Wang Jingbo Wang Yongjing Tang Wen Zheng Zhitao Ying Lingyan Ping Chen Zhang Meng Wu Jun Zhu Yan Xie |
| author_facet | Yanfei Liu Yuqin Song Shubo Zuo Xian Zhang Hui Liu Jingwen Wang Jingbo Wang Yongjing Tang Wen Zheng Zhitao Ying Lingyan Ping Chen Zhang Meng Wu Jun Zhu Yan Xie |
| author_sort | Yanfei Liu |
| collection | DOAJ |
| description | IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r PTCL.MethodsEligible patients with r/r PTCL were enrolled and received camrelizumab 200 mg intravenously every 2 weeks and apatinib 500 or 250 mg orally once daily, 4 weeks as a cycle. The primary endpoint was overall response rate (ORR).ResultsA total of 20 patients were enrolled and received study medications in the study, with a median number of prior treatment line of 3 (range 1-6). At the cutoff date of March 4, 2022, the median follow-up was 27.2 months (range: 0.5-39.9), and three patients remained on treatment. Six patients had early discontinuation without tumor response evaluation. For all patients, the ORR was 30% (6/20) (95% confidence interval [CI], 11.9% to 54.3%), with two patients (10%) achieving complete response. The median progression-free survival (PFS) and median overall survival for all patients were 5.6 months (95% CI, 1.8 to not reached) and 16.7 months (95% CI, 2.8 to not reached), respectively. Patients with PD-L1 expression ≥50% (3 patients) had a numerically higher ORR and longer median PFS than those with PD-L1 expression < 50% (5 patients). The most commonly reported grade 3 or higher adverse events were hyperlipidemia (15%), hypokalemia (15%) and anemia (15%). No treatment-related deaths occurred.DiscussionIn this study, PD-1 inhibitors plus low-dose antiangiogenic drugs presented preliminary antitumor activity and manageable toxicity in patients with r/r PTCL. |
| first_indexed | 2024-04-09T19:40:54Z |
| format | Article |
| id | doaj.art-47f5da73004a4bf99dbec33371dabaaf |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T19:40:54Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-47f5da73004a4bf99dbec33371dabaaf2023-04-04T05:39:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11281721128172Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II studyYanfei Liu0Yuqin Song1Shubo Zuo2Xian Zhang3Hui Liu4Jingwen Wang5Jingbo Wang6Yongjing Tang7Wen Zheng8Zhitao Ying9Lingyan Ping10Chen Zhang11Meng Wu12Jun Zhu13Yan Xie14Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaDepartment of Lymphoma, Jilin Guowen Hospital, Siping, ChinaDepartment of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang, ChinaDepartment of Hematology, Beijing Hospital, Beijing, ChinaDepartment of Hematology, Beijing Tongren Hospital, Beijing, ChinaDepartment of Hematology, Aerospace Central Hospital, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaIntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r PTCL.MethodsEligible patients with r/r PTCL were enrolled and received camrelizumab 200 mg intravenously every 2 weeks and apatinib 500 or 250 mg orally once daily, 4 weeks as a cycle. The primary endpoint was overall response rate (ORR).ResultsA total of 20 patients were enrolled and received study medications in the study, with a median number of prior treatment line of 3 (range 1-6). At the cutoff date of March 4, 2022, the median follow-up was 27.2 months (range: 0.5-39.9), and three patients remained on treatment. Six patients had early discontinuation without tumor response evaluation. For all patients, the ORR was 30% (6/20) (95% confidence interval [CI], 11.9% to 54.3%), with two patients (10%) achieving complete response. The median progression-free survival (PFS) and median overall survival for all patients were 5.6 months (95% CI, 1.8 to not reached) and 16.7 months (95% CI, 2.8 to not reached), respectively. Patients with PD-L1 expression ≥50% (3 patients) had a numerically higher ORR and longer median PFS than those with PD-L1 expression < 50% (5 patients). The most commonly reported grade 3 or higher adverse events were hyperlipidemia (15%), hypokalemia (15%) and anemia (15%). No treatment-related deaths occurred.DiscussionIn this study, PD-1 inhibitors plus low-dose antiangiogenic drugs presented preliminary antitumor activity and manageable toxicity in patients with r/r PTCL.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/fullperipheral T-cell lymphomaPD-1 inhibitorapatinibimmunotherapycamrelizumab |
| spellingShingle | Yanfei Liu Yuqin Song Shubo Zuo Xian Zhang Hui Liu Jingwen Wang Jingbo Wang Yongjing Tang Wen Zheng Zhitao Ying Lingyan Ping Chen Zhang Meng Wu Jun Zhu Yan Xie Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study Frontiers in Immunology peripheral T-cell lymphoma PD-1 inhibitor apatinib immunotherapy camrelizumab |
| title | Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study |
| title_full | Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study |
| title_fullStr | Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study |
| title_full_unstemmed | Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study |
| title_short | Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study |
| title_sort | antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral t cell lymphoma an open label multicenter phase ii study |
| topic | peripheral T-cell lymphoma PD-1 inhibitor apatinib immunotherapy camrelizumab |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full |
| work_keys_str_mv | AT yanfeiliu antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT yuqinsong antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT shubozuo antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT xianzhang antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT huiliu antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT jingwenwang antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT jingbowang antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT yongjingtang antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT wenzheng antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT zhitaoying antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT lingyanping antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT chenzhang antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT mengwu antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT junzhu antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy AT yanxie antitumoractivityandsafetyofcamrelizumabcombinedwithapatinibinpatientswithrelapsedorrefractoryperipheraltcelllymphomaanopenlabelmulticenterphaseiistudy |